Phase 3 Peripheral Neuropathy Trial, Recruiting NCT06872437 Sponsor: Groupe Hospitalier Diaconesses Croix Saint-Simon Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 3 Peripheral Neuropathy Trial, Recruiting

NCT06872437
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have given their consent to take part in the study
  • People who are covered by a social security or health insurance plan
  • People who have been diagnosed with pudendal neuralgia (a type of chronic pelvic nerve pain), confirmed using a specific set of diagnostic criteria known as the "modified Nantes criteria"
  • People whose MRI scan results are normal or do not show any condition that would explain their pain
  • People whose pain has not responded well enough to medication — specifically, where at least one anti-seizure medication and one antidepressant (both used here for nerve pain) have been tried at the highest tolerable dose without reducing pain sufficiently, or where side effects prevented the dose from being increased to the maximum allowed level

Who may not be able to join:

  • People who are under a legal protection or guardianship order
  • People who are pregnant or breastfeeding
  • People who currently have an active general or local infection, including certain types of infections near the anal area
  • People who have a known neurological condition that could explain their pain
  • People who have a psychiatric condition that requires medication to manage
  • People who take blood-thinning medications or have a condition affecting blood clotting
  • People who have a known sensitivity or allergic reaction to lidocaine hydrochloride or other local anaesthetic medications
  • People who have a condition called recurrent porphyria (a rare disorder affecting the nervous system or skin)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Groupe Hospitalier Diaconesses Croix Saint-Simon
Registry
ClinicalTrials.gov
Start date
8 December 2023
Est. completion
8 March 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Comparison between the two treatment arms (lidocaine vs.saline) of the rate of patients with a decrease of at least 3 points on a visual 3 points on a visual analogue pain scale (VAS) between inclusion and

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov